Atiprimod
Atiprimod (Azaspirane) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 123018-47-3
- 分子式: C22H44N2
- 分子量:336.60
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
Atiprimod (0-7 µM, 24 h) decreases viability of GH3 cells, MDA-MB-231 and MDA-MB-468 breast cancer cellsand in a dose-dependent manner[1][2].
Atiprimod (0-3 µM, 24 h) downregulates STAT-1, STAT-3, STAT-5, pSTAT-1, pSTAT-3, pSTAT-5 and GH expressions in GH3 cells[1].
Atiprimod (1-3 µM, 4 days) reduces colony diameter of GH3 cells in hanging drop assay[1].
Atiprimod (1-3 µM, 24 h) triggers ER stress in GH3, MDA-MB-231 and MDA-MB-468 breast cancer cells, as indicated by CHOP activation, dose-dependent Ca2+ release, upregulation of BiP and CHOP, and phosphorylation of AMPK[1][2].
Atiprimod (1-3 µM, 24 h) induces autophagy, apoptosis and triggers ROS generation in GH3, MDA-MB-231 and MDA-MB-468 cells[1][2].
Atiprimod (2 µM, 24 h) enhances viability loss, inhibits growth, and increases subG1 population in STAT3-overexpressing GH3 cells, and prevents upregulation of Atg5, Beclin-1, BiP, CHOP and LC3 cleavage induced by atiprimod in GH3 cells[1].
Atiprimod (0.5-4 μM) inhibits clonogenic growth of AML cell lines (OCIM2, OCI/AML-3, KG-1, K562, HL-60) [3].
Atiprimod (0.5-4 μM, 2 h) decreases phosphorylation of Stat3, Stat5, and protein levels of Jak2 and phospho-Jak2 in K562 cells without affecting Jak2 gene expression[3].
Atiprimod (1-5 μM, 6-48 h) induces apoptosis of MCL cell lines (SP53, MINO, Grant 519, and Jeko-1) and primary MCL cells in both dose- and time-dependent manners, detected by annexin V-binding and TUNEL assays[4].
Atiprimod (5 μM, 1-2 h) inhibits IL-6-induced phosphorylation of JAK2/STAT3 and Akt, and TNF-α-induced phosphorylation of IκB and NFκB p65, while downregulating Mcl-1 in MM.1S cells[5].
Atiprimod (0.6-2.5 μM, 48 h) inhibits growth of MM.1S and U266 cells adherent to BMSCs, and reduces IL-6 and VEGF secretion in BMSCs (alone or with MM cells)[5].
Atiprimod (1.25-2.5 μM, 6 h) inhibits capillary network formation in HUVECs without cytotoxicity, and reduces VEGF secretion in HUVECs and BMSCs[5].
Atiprimod (0.1-0.8 μM, 72 h) inhibits proliferation of mouse FDCP-EpoR JAK2WT cells (IC50 = 0.69 μM), FDCP-EpoR JAK2V617F cells (IC50 = 0.42 μM), human SET-2 cells (JAK2V617F-positive, IC50 = 0.53 μM) and CMK cells (JAK3-mutant, IC50 = 0.79 μM) in a dose-dependent manner[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GH3, MDA-MB-231 and MDA-MB-468 cells
-
Concentration:1, 2, 3 µM
-
Incubation Time:24 h
-
Result:Reduced the expressions of STAT-1, STAT-3, STAT-5, pSTAT-1, pSTAT-3, pSTAT-5, GH, Bcl-2, Bcl-XL and p62.
Increased the expressions of Atg5, Atg12, Beclin-1, LC-3II, BiP, CHOP, p-PERK, p-AMPK, eIF-2, p70S6K, p53, p-p53, Bax, PUMA and Bim.
Activated caspase-3, -6, -7 and PARP cleavage.
-
Cell Line:MCL cell lines (SP53, MINO, Grant 519, and Jeko-1)
-
Concentration:1, 2, 4, 5 µM
-
Incubation Time:6, 12, 24, 48 h
-
Result:Activated caspase-9, caspase-3, and cleaves PARP in MCL cells.
up-regulateD Bax, Bad, and phosphorylated Bcl-2.
Atiprimod (50 mg/kg, i.v., once daily, 6 consecutive days) demonstrates significant in vivo anti-tumor efficacy in OPM1 human multiple myeloma xenograft SCID mouse models[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SP53 or Grant 519 cells (5 × 106 in 50 µL PBS) were subcutaneously inoculated into the right flank of 6- to 8-week-old male CB-17 SCID mice[4]
-
Dosage:25 mg/kg
-
Administration:i.p. once daily for 6 consecutive days
-
Result:Achieved significant tumor growth inhibition in SP53 and Grant 519 MCL xenograft SCID mouse models.
Reduced tumor volume and decreased levels of circulating human β2-microglobulin.
Prolonged survival of tumor-bearing mice.
-
Animal Model:OPM1 cells (5 × 106 in 100 µL RPMI-1640 medium) were subcutaneously inoculated into the interscapular area of 6- to 8-week-old male CB-17 SCID mice[5]
-
Dosage:50 mg/kg
-
Administration:i.v. once daily for 6 consecutive days
-
Result:Achieved significant tumor growth inhibition in OPM1 human multiple myeloma xenograft SCID mouse models.
Reduced tumor volume in tumor-bearing mice.
化学情報
-
CAS 番号 123018-47-3
-
分子量 336.60
-
分子式 C22H44N2
-
SMILES
CCN(CCCN1CCC2(CCC(CCC)(CC2)CCC)C1)CC
-
別名
Azaspirane ; SKF 106615-12; SKF 106615A12
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Coker-Gurkan A, et al. Atiprimod induce apoptosis in pituitary adenoma: Endoplasmic reticulum stress and autophagy pathways. J Cell Biochem. 2019 Dec;120(12):19749-19763. [Content Brief]
[2]. Coker-Gurkan A, et al Atiprimod triggered apoptotic cell death via acting on PERK/eIF2α/ATF4/CHOP and STAT3/NF-ΚB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells. Mol Biol Rep. 2021 Jun;48(6):5233-5247. [Content Brief]
[3]. Faderl S, et al. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan;31(1):91-5. [Content Brief]
[4]. Wang M, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15;109(12):5455-62. [Content Brief]
[5]. Hamasaki M, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 1;105(11):4470-6. [Content Brief]
[6]. Quintás-Cardama A, et al. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct;29(5):818-26. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Atiprimod 関連分類
HY-13559 関連分類
Powered by Bioz